- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Nanoparticles made of metals such as gold or iron oxide show tremendous promise as contrast agents for molecular imaging, but turning promise into clinical utility requires adding tumor targeting molecules to the surfaces of these nanoparticles. A new coating technique that uses oligonucleotides to tether targeting molecules securely to a nanoparticle's surface could provide a versatile method for creating such targeted nanoparticles.
Reporting their work in the journal Bioconjugate Chemistry, Rebecca Richards-Kortum, Ph.D., and colleagues describe a method for using sulfur-containing derivatives of DNA that bind tightly to the surface of gold nanoparticles. The researchers then use a complementary DNA sequence to link the DNA-coated nanoparticle to a targeting ligand. The resulting oligonucleotide-linked nanoparticles are much smaller than similar imaging agents constructed by absorbing targeting proteins directly onto the surfaces of gold nanoparticles. The oligonucleotide tethers also produce a construct that is more stable under physiological conditions.
Using their new methodology, the investigators created imaging agents designed to detect the epidermal growth factor receptor (EGF) using either an EGF peptide or an antibody that binds to the receptor. The researchers also created a contrast agent designed to recognize the folate receptor that is overexpressed in many tumors, as well as a contrast agent that also contains a fluorescent marker that allows for multimodal imaging using both confocal reflectance imaging and standard fluoresence imaging. In each case, the contrast agents provided a significant signal boost that was detected easily using the appropriate imaging technique.
This work is detailed in the paper "Oligonucleotide-coated metallic nanoparticles as a flexible platform for molecular imaging agents." This paper was published online in advance of print publication. An abstract of this paper is available through PubMed.
About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © National Cancer InstituteIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
“Cysteine Rose” Wins 2016 Thermo Fisher Scientific Electron Microscopy Image Contest: Thermo Fisher honors Andrea Jacassi of the Italian Institute of Technology for image of cysteine crystals using focused ion beam techniques March 27th, 2017
ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017
Leti and HORIBA Scientific to Host Webinar on Ultrafast Characterization Tool: Plasma Profiling Time-of-Flight Mass Spectrometer Tool Cuts Optimization Time In Layer Deposition and Fabrication of Wide Range of Applications March 27th, 2017